

semantics driven applications

Steve Harris

James Martin Research Fellow

Department of Computer Science


University of Oxford

It commonly happens that there is no one conclusive study but 'meta-analysis' gives you a combined result from every randomised trial that has been done around the world. For example, the drug Tamoxifen an oestrogen blocker that may prevent breast cancer cells growing was the object of forty-two studies world-wide of which only four or five had shown significant benefits. But this did not mean that Tamoxifen did not protect against breast cancer. 'When we put all the studies together it was blindingly obvious that it does you don't have to be a medical statistician to see that. Nor do you need to be an economist to see the advantages of saving tens of thousands of lives with this inexpensive drug'

Prof. Richard Gray, University of Birmingham

cancergrid

- not just about cancer
- definitely not a computing grid
- a project to develop tools for
 - semantic annotation of clinical trials
 - generation of trial data management software
 - tooling for meta-analysis



cancergrid

software engineering @ oxford

- part of the department of computer science
- teaching and research in all matters of software engineering
 - from human factors
 - to software engineering mathematics
 - for professional software engineers
- oxford metadata group
 - dedicated to research into semantic frameworks
 - develop open source tooling for medical research

META-ANALYSIS

early breast cancer trialists' collaborative group

- initiated in 1983
- hundreds of institutions worldwide
- consensus on 30 variables, a data model and submission format – now increasing to 200 variables
- analyse data every 5 years
- computable data and follow-up for 200,000 cases in the 2000 review
- rock-solid evidence base for the treatment of early breast cancer

doesn't always work

- systematic review of TP53 and Platinum response
 - 75 clinical studies
 - 8331 patients
 - prognostic value of TP53 mutation in ovarian cancer
 - no conclusions could be drawn
 - most of the study metadata was missing
 - insufficient detail about the IHC
 - only some exons sequenced

why?

- not enough metadata – especially identifiers
- not enough data standards – incompatible representations
- not enough data management – data captured only for original purpose

FORMS AND DATASET REGISTRATION

[List Results](#)

Refine Search

[Results by Topic](#)

[Results on Map](#)

[Search Details](#)

Refine your search here or [Start Over](#).

[Expert Search](#)

Change your search with any or all of the fields below.
Search within your current results by adding more search terms.

[Search Terms:](#)

[Help](#)

[Recruitment:](#)

[Study Results:](#)

[Study Type:](#)

Targeted Search:

[Conditions:](#)

[Interventions:](#)

[Outcome Measures:](#)

[Lead Sponsors:](#)

[Sponsors:](#)

[Study IDs:](#)

Exact Match

Exact Match

Locations:

[State 1:](#)

[Country 1:](#)

[State 2:](#)

[Country 2:](#)

[State 3:](#)

[Country 3:](#)

[Location Terms:](#)

Additional Criteria:

List Results

[Refine Search](#)

[Results by Topic](#)

[Results on Map](#)

[Search Details](#)

Found 382 studies with search of: prostate | radiotherapy

[Hide studies that are not seeking new volunteers.](#)

[+ Display Options](#)

Rank	Status	Study
1	Recruiting	<p>The ELDORADO (Eligard®, Docetaxel and Radiotherapy) Study</p> <p>Condition: Prostatic Neoplasms Interventions: Drug: Docetaxel; Drug: Leuprolide Acetate (Eligard®); Radiation: Intensity-Modulated Radiotherapy</p>
2	Active, not recruiting	<p>A Phase III Intensity Radiotherapy Dose Escalation for Prostate Cancer Using Hypofractionation</p> <p>Condition: Prostate Cancer Interventions: Radiation: Conventional Fractionated Intensity Modulated Radiotherapy; Radiation: Hypofractionated Intensity Modulated Radiotherapy</p>
3	Recruiting	<p>Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer</p> <p>Condition: Prostate Cancer Interventions: Drug: bicalutamide; Drug: buserelin; Drug: flutamide; Drug: goserelin acetate; Drug: leuprolide acetate; Drug: triptorelin; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy</p>
4	Active, not recruiting	<p>MRI-Guided Placement of Imaging Markers in Patients With Prostate Cancer Undergoing External-Beam Radiation Therapy</p> <p>Condition: Prostate Cancer Interventions: Procedure: implanted fiducial-based imaging; Procedure: magnetic resonance imaging; Radiation: 3-dimensional conformal radiation therapy; Radiation: external beam radiation therapy; Radiation: radiation therapy treatment planning/simulation</p>
5	Active, not recruiting	<p>Internal Radiation Therapy With or Without External-Beam Radiation Therapy in Treating Patients With Localized Prostate Cancer</p> <p>Condition: Prostate Cancer Interventions: Radiation: brachytherapy; Radiation: hypofractionated radiation therapy; Radiation: image-guided radiation therapy; Radiation: intensity-modulated radiation therapy</p>
6	Recruiting	<p>Radiation Therapy in Treating Patients Receiving Hormone Therapy for Prostate Cancer</p> <p>Condition: Prostate Cancer Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy</p>
7	Completed	<p>Radical Radiotherapy by External Beam Radiation Versus Radical Radiotherapy With Temporary Iridium Implant Plus External Beam Radiation in Carcinoma of the Prostate</p>

Study 2 of 382 for search of: prostate | radiotherapy
[Previous Study](#) [Return to Search Results](#) [Next Study](#)

A Phase III Intensity Radiotherapy Dose Escalation for Prostate Cancer Using Hypofractionation

This study is ongoing, but not recruiting participants.

Study NCT00667888 | Information provided by M.D. Anderson Cancer Center
 First Received: April 24, 2008 | Last Updated: September 29, 2010 | [History of Changes](#)

Tracking Information

First Received Date: April 24, 2008

Last Updated Date: September 29, 2010

Start Date: 01/01/2013

Estimated Primary Completion Date: January 2013 (final data collection date for primary outcome measure)

Current Primary Outcome Measures: Number of Patients with Incidence of Rising PSA [Time Frame: PSA every 3 months for the first 2 years, every 6 months for years 3-5, and yearly thereafter] [Designated as safety issue: Yes]

Original Primary Outcome Measures: The goal is to compare using external beam radiotherapy with intensity modulated beams for fewer days at a higher dose per day to the same type of therapy for more days at a lower dose per day in the treatment of prostate cancer. [Time Frame: 12 Years] [Designated as safety issue: No]

Change History: Complete list of historical versions of study NCT00667888 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures: The safety of these treatments will also be studied and compared. [Time Frame: 12 Years] [Designated as safety issue: Yes]

Study 2 of 382 for search of: prostate | radiotherapy

← [Previous Study](#) [Return to Search Results](#) [Next Study](#) →

[Full Text View](#) [Tabular View](#) [No Study Results Posted](#) [Related Studies](#)

A Phase III Intensity Radiotherapy Dose Escalation for Prostate Cancer Using Hypofractionation

This study is ongoing, but not recruiting participants.

Study NCT00667888 | Information provided by M.D. Anderson Cancer Center
 First Received: April 24, 2008 | Last Updated: September 29, 2010 | [History of Changes](#)

Tracking Information

First Received Date ICMJJE	April 24, 2008
Last Updated Date	September 29, 2010
Start Date ICMJJE	January 2001
Estimated Primary Completion Date	January 2013 (final data collection date for primary outcome measure)
Current Primary Outcome Measures ICMJJE (submitted: January 4, 2010)	Number of Patients with Incidence of Rising PSA [Time Frame: PSA every 3 months for the first 2 years; every 6 months for years 3-5; and yearly thereafter] [Designated as safety issue: Yes]
Original Primary Outcome Measures ICMJJE (submitted: April 25, 2008)	The goal is to compare using external beam radiotherapy with intensity modulated beams for fewer days at a higher dose per day to the same type of therapy for more days at a lower dose per day in the treatment of prostate cancer. [Time Frame: 12 Years] [Designated as safety issue: No]
Change History	Complete list of historical versions of study NCT00667888 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ICMJJE	The safety of these treatments will also be studied and compared. [Time Frame: 12 Years] [Designated as safety issue: Yes]
Original Secondary Outcome Measures ICMJJE (submitted: April 25, 2008)	The safety of these treatments will also be studied and compared. [Time Frame: 12 Years] [Designated as safety issue: Yes]

Descriptive Information

Study Title: A Phase III Intensity Radiotherapy Dose Escalation for Prostate Cancer Using Hypofractionation

Study Summary: Treatment: The goal of this clinical research study is to compare using external beam radiotherapy with intensity modulated beams for fewer days at a higher dose per day to the same type of therapy for more days at a lower dose per day in the treatment of prostate cancer. The safety of these treatments will also be studied and compared.
Objectives:
 1. To assess the ability of 70 Gy in 30 fractions (HR70) or 80 Gy (HR80) compared to 78 Gy in 42 fractions (HR42). The most and least likely to experience a rising PSA, progression to local control, freedom from distant relapse.
 2. To establish local failure by biopsy of the prostate when objective tests (PSA, ultrasound, DRE) suggest relapse.
 3. To establish the value of PSA when Gleason 2, 3, 4 and 5 were used to determine using conventional vs intense fractionation, and local control failure.
 4. To establish the potential prostate biopsy related to assess prospectively the predictive value of various potential prognostic factors, such as p53, bcl-2, Sox4 and Ki-67.
 5. To assess the prognostic value of pretreatment serum testosterone, sex hormone binding globulin, and estradiol.

Design: Patients in this study will be randomly placed (in the form of a coin) to be in one of two treatment groups. There is an equal chance of being in either group.
Patients in Group 1 will be treated with intensity modulated radiotherapy (IMRT). These patients will receive 42 treatments, 5 days per week for 8 weeks. The total dose will be 78 Gy in 42 fractions (HR42) delivered in 8 weeks.
Patients in Group 2 will also be treated with IMRT. However, these patients will only receive 30 treatments, 5 days per week, over 6 weeks. The total dose will be 70 Gy in 30 fractions (HR70) delivered in 6 weeks.
 Each external beam treatment requires about 10-20 minutes. However, patients can expect to spend 20-30 minutes on the treatment table because imaging measurements of prostate position will be done before each treatment. The total time in the radiation department with treatment may be about 1 hour.
 After the radiation is completed, patients will have a PSA blood test every 1 month for 2 years, every 6 months for years 3-5, and then annually. You will be contacted every 6 months during the first 2 years regarding treatment after the completion of treatment. You annually. A health history of the prostate will be performed if these tests suggest recurrences.
 There is no charge for treatment. 225 patients will take part in this study. This study will take place at M.D. Anderson and possibly some affiliated hospitals.

Study Phase: Phase III

Study Type: HR42
 HR70
 HR80

Study Design: HR42
 HR70
 HR80
 Allocation: Randomized
 Intervention Model: Superiority/Inferiority Design
 Treatment Comparison: Parallel Assignment
 Blinding: Open Label
 Primary Purpose: Treatment

Condition: HR42
 HR70
 HR80

Intervention: HR42
 HR70
 HR80

Study Arms: HR42
 HR70
 HR80

Comparison Group: HR42
 HR70
 HR80

Other Arms: HR42
 HR70
 HR80

Other Study ID: HR42
 HR70
 HR80

Responsible Party: Deborah A. Kuban, MD/PhD, UT M.D. Anderson Cancer Center
 M.D. Anderson Cancer Center

Study Sponsor: M.D. Anderson Cancer Center

Collaborator: M.D. Anderson Cancer Center

Investigator: M.D. Anderson Cancer Center

Information Provided By: M.D. Anderson Cancer Center

Verification Date: September 2010

ICMJJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization (CTD)

Descriptive Information

[List Results](#)

[Refine Search](#)

[Results by Topic](#)

[Results on Map](#)

[Search Details](#)

Found 122 studies with search of: "Prostatic Diseases" | radiotherapy | NIH OR NCI

[Hide studies that are not seeking new volunteers.](#)

[+ Display Options](#)

Rank	Status	Study
1	Active, not recruiting	<p>MRI-Guided Placement of Imaging Markers in Patients With Prostate Cancer Undergoing External-Beam Radiation Therapy</p> <p>Condition: Prostate Cancer Interventions: Procedure: implanted fiducial-based imaging; Procedure: magnetic resonance imaging; Radiation: 3-dimensional conformal radiation therapy; Radiation: external beam radiation therapy; Radiation: radiation therapy treatment planning/simulation</p>
2	Active, not recruiting	<p>Amifostine to Protect the Rectum During External Beam Radiotherapy for Prostate Cancer</p> <p>Condition: Prostatic Neoplasms Interventions: Drug: Amifostine trihydrate; Radiation: radiation therapy</p>
3	Completed	<p>Radiation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer</p> <p>Condition: Prostate Cancer Interventions: Biological: aldesleukin; Biological: recombinant fowlpox-prostate specific antigen vaccine; Biological: recombinant vaccinia prostate-specific antigen vaccine; Biological: recombinant vaccinia-B7.1 vaccine; Biological: sargramostim; Radiation: brachytherapy; Radiation: radiation therapy</p>
4	Recruiting	<p>MRI-Guided Radiation Therapy in Treating Patients With Prostate Cancer</p> <p>Condition: Prostate Cancer Intervention: Radiation: radiation therapy</p>
5	Recruiting	<p>MRI-Guided Radiation Therapy in Treating Patients With Prostate Cancer</p> <p>Condition: Prostate Cancer Intervention: Radiation: radiation therapy</p>
6	Active, not recruiting	<p>Internal Radiation Therapy With or Without External-Beam Radiation Therapy in Treating Patients With Localized Prostate Cancer</p> <p>Condition: Prostate Cancer Interventions: Radiation: brachytherapy; Radiation: hypofractionated radiation therapy; Radiation: image-guided radiation therapy; Radiation: intensity-modulated radiation therapy</p>
7	Recruiting	<p>Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer</p> <p>Condition: Prostate Cancer Interventions: Drug: bicalutamide; Drug: buserelin; Drug: flutamide; Drug: goserelin acetate; Drug: leuprolide acetate; Drug: triptorelin; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy</p>
8	Recruiting	<p>Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer</p> <p>Condition: Prostate Cancer Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy; Radiation: samarium Sm 153 lexidronam pentasodium</p>
9	Active, not recruiting	<p>Radiation Therapy in Treating Patients With Stage II Prostate Cancer</p> <p>Condition: Prostate Cancer</p>

Study 9 of 122 for search of: "Prostatic Diseases" | radiotherapy | NIH OR NCI

[← Previous Study](#) [Return to Search Results](#) [Next Study →](#)

[Full Text View](#)

Tabular View

[No Study Results Posted](#)

[Related Studies](#)

Radiation Therapy in Treating Patients With Stage II Prostate Cancer

This study is ongoing, but not recruiting participants.

Study NCT00331773 Information provided by National Cancer Institute (NCI)
First Received: May 30, 2006 Last Updated: December 17, 2009 [History of Changes](#)

Tracking Information

First Received Date <small>ICMJE</small>	May 30, 2006
Last Updated Date	December 17, 2009
Start Date <small>ICMJE</small>	April 2006
Estimated Primary Completion Date	May 2011 (final data collection date for primary outcome measure)
Current Primary Outcome Measures <small>ICMJE</small> (submitted: December 25, 2007)	Disease-free survival at 5 years as measured by Kaplan-Meier [Designated as safety issue: No]
Original Primary Outcome Measures <small>ICMJE</small> (submitted: November 9, 2006)	Disease-free survival at 5 years as measured by Kaplan-Meier
Change History	Complete list of historical versions of study NCT00331773 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures <small>ICMJE</small> (submitted: November 8, 2008)	<ul style="list-style-type: none">• Time to failure [Designated as safety issue: No]• Disease-specific survival [Designated as safety issue: No]• Freedom from biochemical recurrence (FFBR) [Designated as safety issue: No]• Overall survival [Designated as safety issue: No]• Incidence of GU and GI acute and late toxicity [Designated as safety issue: Yes]• Statistical modeling of genomic biomarkers [Designated as safety issue: No]



CDE Browser



[Admin Tool](#) |
 [Curation Tool](#) |
 [NCI Metathesaurus](#) |
 [NCI Terminology Server](#) |
 [Sentinel Tool](#) |
 [UML Model Browser](#) |
 [What's new](#)

Data Element Search

Search by Name

No Matches

[Search preferences](#)

[Basic search](#)

caDSR Contexts>>CTEP (NCI Cancer Therapy Evaluation Program)>>Protocol Forms>>RTOG-0415

- Exact phrase
- All of the words
- At least one of the words

331773

Tip: To search for partial words or phrases use the * as a wildcard.

Note: Default settings exclude Test and Training Context views from the tree and certain 'non-released' Workflow and Registration statuses. Click the 'Search Preferences' link above to view or change the exclusion criteria. Search Preferences' will be reset to default settings when the 'New Search' button is clicked on the search results page or 'caDSR Context' in the Tree.

Search in the following field(s)

- ALL
- Long Name
- Short Name
- Preferred Question Text

Tip: Use Shift or Ctrl to select multiple fields.

Search by Concept

Concept Name	<input type="text"/>	Concept Code	<input type="text"/>
--------------	----------------------	--------------	----------------------

Search by Attributes

Public ID	<input type="text"/>	Alternate Name	<input type="text"/>
Data Element Concept	<input type="text"/> Clear	Alternate Name Type(s)	ALL 3.1 VM Name ABBREVIATION
Classification	<input type="text"/> Clear	Object Class	<input type="text"/>
Value Domain	<input type="text"/> Clear	Property	<input type="text"/>
Permissible Value	<input type="text"/>		

Exact phrase
 All words
 At least one word

Limit search results using filters

Version	<input checked="" type="radio"/> Latest Version <input type="radio"/> All Versions	Context Use	Owned By/Used By
	<input type="text"/>		<input type="text"/>

Refresh tree

- caDSR Contexts
 - BRIDG (BRIDG Collaboration)
 - caBIG (NCI cancer Biomedical Informatics C)
 - caBIG CDE Data Standards (Shortcut)
 - caCORE (NCI Core Infrastructure)
 - CCR (NCI Center for Cancer Research)
 - CDISC (Clinical Data Interchange Standards)
 - CIP (NCI Cancer Imaging Program)
 - CTEP (NCI Cancer Therapy Evaluation Progra)
 - DCP (NCI Division of Cancer Prevention)
 - EDRN (NCI Early Research Detection Progra)
 - HITSP (Health Information Technology Stan
 - NCRI (National Cancer Research Institute, U
 - NHLBI (National Heart, Lung and Blood Insti
 - NICHD (National Institute of Child Health and
 - NIDCR (National Institute of Dental and Cran
 - NINDS (National Institute of Neurological Dis
 - PS&CC (NCI Population Sciences & Cancer
 - SPOREs (NCI Specialized Programs of Rese

- At least 30 days since prior finasteride
- At least 90 days since prior dutasteride
- No concurrent neoadjuvant or adjuvant hormonal therapy
- Concurrent warfarin or other blood-thinning agents allowed

Gender	Male
Ages	18 Years and older
Accepts Healthy Volunteers	No
Contacts ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ICMJE	United States, Canada

Administrative Information

NCT ID ICMJE	NCT00331773
Other Study ID Numbers ICMJE	CDR000048119, RTOG-0415
Responsible Party	Walter John Curran, Jr, Radiation Therapy Oncology Group
Study Sponsor ICMJE	Radiation Therapy Oncology Group
Collaborators ICMJE	National Cancer Institute (NCI)
Investigators ICMJE	Study Chair: W. Robert Lee, MD Duke University
Information Provided By	National Cancer Institute (NCI)
Verification Date	November 2009

[ICMJE](#) Data element required by the [International Committee of Medical Journal Editors](#) and the [World Health Organization ICTRP](#)

[Contact Help Desk](#)

[Lister Hill National Center for Biomedical Communications](#), [U.S. National Library of Medicine](#),
[U.S. National Institutes of Health](#), [U.S. Department of Health & Human Services](#),
[USA.gov](#), [Copyright](#), [Privacy](#), [Accessibility](#), [Freedom of Information Act](#)





CDE Browser



CDE Cart

Home

FormBuilder

Help

[Admin Tool](#) | [Curation Tool](#) | [NCI Metathesaurus](#) | [NCI Terminology Server](#) | [Sentinel Tool](#) | [UML Model Browser](#) | [What's new](#)

Data Element Search

Search for Data Elements

No Matches

[Search preferences](#)

[Advanced search](#)

caDSR Contexts>>CTEP (NCI Cancer Therapy Evaluation Program)>>Protocol Forms>>RTOG-0415

- Exact phrase
- All of the words
- At least one of the words

Name ▼

Tip: This is an exact match search. To search for partial words or phrases use the * as a wildcard.

Note: Default settings exclude Test and Training Context views from the tree and certain 'non-released' Workflow and Registration statuses. Click the 'Search Preferences' link above to view or change the exclusion criteria. Search Preferences will be reset to default settings when the 'New Search' button is clicked on the search results page or 'caDSR Context' in the Tree.

[Search](#) [Clear](#) [New Search](#)

Search Results

Results fewer than expected? Check Search Preferences

Long Name	Preferred Question Text	Owned By	Used By Context	Registration	Workflow Status	Public ID	Version
No data elements matching the search criteria found.							

Refresh tree

- caDSR Contexts
 - BRIDG (BRIDG Collaboration)
 - caBIG (NCI cancer Biomedical Informatics Grid)
 - caBIG CDE Data Standards (Shortcut)
 - caCORE (NCI Core Infrastructure)
 - CCR (NCI Center for Cancer Research)
 - CDISC (Clinical Data Interchange Standards Cons)
 - CIP (NCI Cancer Imaging Program)
 - CTEP (NCI Cancer Therapy Evaluation Program)
 - Classifications
 - Protocol Forms
 - 8214
 - 8788
 - ACOSOG-Z1031
 - ACOSOG-Z1041
 - ACOSOG-Z1071
 - ACOSOG-Z1072
 - ACOSOG-Z4032
 - ACOSOG-Z4051
 - ACOSOG-Z5041
 - ACOSOG-Z6041
 - ACOSOG-Z6051
 - Adverse Events Mapping
 - AMC-044
 - AMC-038
 - AMC-040
 - AMC-042
 - AMC-045
 - AMC-046
 - AMC-047
 - AMC-048
 - AMC-050
 - AMC-051

User: Public User

[Privacy Notice](#)

Version 4.0.1.1 Build 2

Please send comments and suggestions to ncicb@pop.nci.nih.gov



Search Results [Search within results](#)

Results fewer than expected? [Check Search Preferences](#)

[\[Download Data Elements to Prior Excel\]](#)
[\[Download Data Elements to Excel\]](#)
[\[Download Data Elements as XML\]](#)
[\[Download CDE Browser DTDs\]](#)

Sort order: (Default) Registration Status>>Workflow Status>>Long Name [Ascending]

1 - 100 of 107 [Next 7](#)

- [RTOG 0825](#)
- [RTOG 0834](#)
- [RTOG 0848](#)
- [RTOG 0920](#)
- [RTOG 1010](#)
- [RTOG 1016](#)
- [RTOG P-0011](#)
- [RTOG P-0126](#)
- [RTOG-0320](#)
- [RTOG-0412](#)
- [RTOG-0415](#)
 - [RTOG-0415 AE: Adverse Event Evaluati](#)
 - [RTOG-0415 F1: Follow-up Form](#)
 - [RTOG-0415 I1: Initial Evaluation Form](#)
 - [RTOG-0415 T1: Radiotherapy Form](#)
- [RTOG-0421](#)
- [RTOG-0436](#)
- [RTOG-0521](#)
- [RTOG-0522](#)
- [RTOG-0525](#)
- [RTOG-1014](#)
- [RTOG0214](#)
- [RTOG0232](#)
- [S0023](#)
- [S0100](#)
- [S0124](#)
- [S0201](#)
- [S0205](#)
- [S0210](#)
- [S0221](#)
- [S0226](#)
- [S0227](#)
- [S0230](#)
- [S0303](#)
- [S0307](#)

<input type="checkbox"/>	Long Name	Preferred Question Text	Owned By	Used By Context	Registration Status	Workflow Status
<input type="checkbox"/>	Performance Status Assessment Eastern Cooperative Oncology Group Scale	Performance Status (ECOG)	CTEP	DCP,SPOREs,caBIG	Standard	RELEASED
<input type="checkbox"/>	Adverse Event Report Ind-3	Has an Adverse Event Expedited Report been submitted?	CTEP		Qualified	RELEASED
<input type="checkbox"/>	Assessment Method Specify	Other Specify	CTEP	CTEP,caBIG	Qualified	RELEASED
<input type="checkbox"/>	Assessment Method Type	Method of Evaluation	CTEP	DCP,NIDCR,caBIG	Qualified	RELEASED
<input type="checkbox"/>	Assessment Performed Date	Date of Assessment	CTEP	DCP,NIDCR	Qualified	RELEASED
<input type="checkbox"/>	Associated Form Submission Date	Due date of corresponding form	CTEP		Qualified	RELEASED
<input type="checkbox"/>	Associated Form Submission Type	Type of corresponding form	CTEP		Qualified	RELEASED
<input type="checkbox"/>	Baseline PSA Date	Date of Baseline PSA	CTEP		Qualified	RELEASED
<input type="checkbox"/>	Biochemical Progression Present Ind-3	Has the patient been diagnosed with biochemical recurrence since submission of the last follow-up form?	CTEP	caBIG	Qualified	RELEASED
<input type="checkbox"/>	Biopsy Date	Date of Biopsy	CTEP	CCR,DCP,PS&CC,caBIG	Qualified	RELEASED
<input type="checkbox"/>	Cancer Follow-Up Status Date	Date of Last Clinical Assessment	CTEP	caBIG	Qualified	RELEASED
<input type="checkbox"/>	Cancer Follow-up Status Ind-3	Has the patient had a documented clinical assessment for this cancer?	CTEP	caBIG	Qualified	RELEASED

Data Element

Check All	Clear All	<input type="checkbox"/>	1	<input type="checkbox"/>	2	<input type="checkbox"/>	3
Public ID	330	323	1285				
Long Name	Common Toxicity Criteria Adverse Event Grade	Common Toxicity Criteria Adverse Event Term Type	CTC Adverse Event Attribution Scale				
Short Name	CTC_AE_GD	CTC_AE_TRM_TP	CTC_AE_ATTR_SCALE				
Document Text	CTC Adverse Event Grade	CTC Adverse Event Term	CTC AE Attribution Code				
Definition	the numeric indicator that describes the severity of an adverse event as defined in CTCAE.	the medical description of the adverse event using NCI CTC terminology.	relation of the causality between the treatment modality and the specific adverse event.				
Owned by Context	CTEP	CTEP	CTEP				
Used by Context	caBIG	SPOREs , CCR , caBIG , DCP	CIP , caBIG , NINDS				
Origin							
Workflow Status	RELEASED	RELEASED	RELEASED				
Registration Status	Qualified	Qualified	Qualified				
Version	8.0	3.0	3.0				

Permissible Values

6 Permissible values

1059 Permissible values

5 Permissible values

Value	Value meaning	Description	Value	Value meaning	Description	Value	Value meaning	Description
0	No adverse event or within normal limits	NO ADVERSE EVENT OR WITHIN NORMAL LIMITS	Acidosis (metabolic or respiratory)	Acidosis NOS	Acidosis NOS	Definite	DEFINITE	No Value Exists
			Acute vascular leak syndrome	Capillary leak syndrome	Capillary leak syndrome	Possible	POSSIBLE	POSSIBLE
1	MILD ADVERSE EVENT	An experience that is usually transient, and requires no special treatment or intervention. The event does not generally interfere with usual daily activities. Includes transient laboratory test alterations.	Adrenal insufficiency	Adrenal insufficiency	Adrenal insufficiency	Probable	PROBABLE	PROBABLE
			Adult respiratory distress syndrome (ARDS)	Adult respiratory distress syndrome	Adult respiratory distress syndrome	Unlikely	UNLIKELY	UNLIKELY
			Albumin, serum-low (hypoalbuminemia)	Blood albumin decreased	Blood albumin decreased	Unrelated	UNRELATED	UNRELATED
			Alcohol intolerance syndrome (antabuse-like syndrome)	Alcohol intolerance syndrome (antabuse-like syndrome)	Alcohol intolerance syndrome (antabuse-like syndrome)			
			Alkaline phosphatase	Blood alkaline phosphatase NOS increased	Blood alkaline phosphatase NOS increased			
2	MODERATE ADVERSE EVENT	An experience that is alleviated with simple therapeutic treatments. The event impacts usual daily activities. Includes laboratory test alterations indicating injury, but without long-term risk.	Alkalosis (metabolic or respiratory)	Alkalosis NOS	Alkalosis NOS			
			Allergic reaction/hypersensitivity (including drug fever)	Hypersensitivity NOS	Hypersensitivity NOS			
			Allergic rhinitis (including sneezing, nasal stuffiness, postnasal drip)	Rhinitis allergic NOS	Rhinitis allergic NOS			
			Allergy/Immunology-Other (Specify)	ALLERGY/IMMUNOLOGY OTHER	an allergy/immunology related item that is not otherwise specified - description required			
3	SEVERE ADVERSE EVENT	Severe adverse event is an experience that requires therapeutic intervention. The event interrupts usual daily activities. If hospitalization is required for treatment it becomes a serious adverse event.	ALT, SGPT (serum glutamic pyruvic transaminase)	Alanine aminotransferase increased	Alanine aminotransferase increased			
			Amylase	Blood amylase increased	Blood amylase increased			
			Anorexia	Anorexia	Loss of appetite.			
4	LIFE-THREATENING OR DISABLING	LIFE-THREATENING OR DISABLING ADVERSE	Apnea	Apnoea	Apnoea			

A22. Children in our class fight a lot

Yes 1 No 2

A23. A few children in my class want to be first all of the time

Yes 1 No 2

A24. Most of the pupils in my class know how to do their work

Yes 1 No 2

ccd200 A21: The class is fun

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	1 Yes	3270	39.9	40.2	40.2
	2 Sometimes	4552	55.5	55.9	96.1
	3 No	321	3.9	3.9	100.0
	Total	8143	99.4	100.0	
Missing	-1 No response	53	.6		
Total		8196	100.0		

ccd205 A22: Children in child's class fight a lot

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	1 Yes	1658	20.2	20.4	20.4
	2 No	6426	78.4	79.1	99.6
	3 Sometimes	36	.4	.4	100.0
	Total	8120	99.1	100.0	
Missing	-1 No response	76	.9		
Total		8196	100.0		

ccd210 A23: A few children in child's class want to be first all the time

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	1 Yes	5446	66.4	67.3	67.3
	2 No	2634	32.1	32.5	99.8
	3 Sometimes	17	.2	.2	100.0
	Total	8097	98.8	100.0	
Missing	-9 Don't know	1	.0		
	-1 No response	98	1.2		
	Total	99	1.2		
Total		8196	100.0		

ccd215 A24: Most of the pupils in child's class know how to do their work

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	1 Yes	7421	90.5	91.4	91.4
	2 No	687	8.4	8.5	99.9
	3 Sometimes	11	.1	.1	100.0
	Total	8119	99.1	100.0	
Missing	-1 No response	77	.9		
Total		8196	100.0		

[browse](#)[search](#)[discover](#)[understand](#)[login](#)

Model: KA SPSS Data Dictionary

[as XSD](#)[as XML](#)

Administered Item - Preferred Name: KA SPSS Data Dictionary

Administered Item Identifier	GB-OUCL-473688D8-1.0
Registration Status <i>explain</i>	Application
Definition	test
Registered By	Steve Harris (Research Fellow) Oxford Comlab

Model Specific Attributes

Mime-type	text/xml
Model Type	SPSS Metadata File
Model Content	Download

Annotations

identifier	names	related to	how
GB-OUCL-5DBCC03E-1.0	Questionnaire version (Form type) ka001	GB-OUCL-AD1B9D47-1.0	sameAs
GB-OUCL-468D233C-1.0	Reaction at birth ka010	GB-OUCL-E5C6AD44-1.0	sameAs
GB-OUCL-1E2D0AEA-1.0	Time until put to breast ka011	GB-OUCL-0126D16D-1.0	sameAs
GB-OUCL-1143400B-1.0	Time next to mum in 1st 2 days ka012	GB-OUCL-0908C607-1.0	sameAs
GB-OUCL-D1C68AD5-1.0	Time next to mum in 1st 2 nights ka013	GB-OUCL-97D01A7B-1.0	sameAs
GB-OUCL-3B4C55B6-1.0	Time next to mum in 1st 2 nights (adjusted) ka013a	GB-OUCL-03B88B17-1.0	sameAs
GB-OUCL-0D5AB2E1-1.0	Admission to SCBU etc ka014	GB-OUCL-13BAAA42-1.0	sameAs
GB-OUCL-92534E0B-1.0	Readmitted to hospital ka020	GB-OUCL-1C06DB4D-1.0	sameAs
GB-OUCL-E8884D70-1.0	Duration of stay ka021	GB-OUCL-241A9B79-1.0	sameAs

Data Element: Baby breast fed

49 738

Administered Item - Preferred Name: Baby breast fed

Administered Item Identifier	GB-OUCL-91690359-1.0
Registration Status <i>explain</i>	Application
Definition	(undefined)
Registered By	Steve Harris (Research Fellow) Oxford Comlab

Value Domain Attributes

Value domain record	Baby breast fed
Conceptual Domain	Baby breast fed
Datatype	xs:string (XML Schema)
Unit of Measure	
Format	not specified
Maximum Character Quantity	not specified
Representation Class	

Valid Values

Valid Values	value	meaning	uri
	-1	Missing	
	1	Always	
	2	Often	
	3	Sometimes	
	4	Never	

Field Names

Field Names	field name	preferred
	ka094	true

Model Reference

Expresses data element concept (full record)	Baby breast fed
Object class	default object class
Property	default property
Precision	0
Example	not specified
Typed by Representation Class	not-specified
Representation Class Qualifier	unqualified
Related data elements	

Reference Documents

Reference Documents	id	language	title	description
	C50D288C6	eng	ka094 Baby breast fed	Frequency plots associated with ALSPAC variables


Category	Frequency
Always	44.1
Often	6.3
Sometimes	2.1
Never	44.0
Missing	0

Representation Class: **Quarter** unqualified

Related data elements

Reference Documents

Reference Documents



Naming

Naming	context	language	name	preferred
	Avon Longitudinal Study of Parents and Children	GB-eng	Baby breast fed	true
	Avon Longitudinal Study of Parents and Children	GB-eng	ka094	false

Administration

Administrative Status <i>explain</i>	noPendingChanges
Administered By	Steve Harris Research Fellow
Created On	not-specified
Effective From	not-specified

Variable: 'Can carer understand child' Speech Q 25 mth

[supersede](#)[edit](#)[as XSD](#)[as XML](#)

Administered Item - Preferred Name: 'Can carer understand child' Speech Q 25 mth

Administered Item Identifier	GB-OUCL-7D36B7A8443C4E7E91E418677117EC83-1 add to cart
Registration Status <i>explain</i>	Recorded
Definition	not-specified
Registered By	Dr. Steve Harris (Researcher, IDH) Oxford Comlab

Value Domain Attributes

Value domain record	Value domain for cf414
Conceptual Domain	Conceptual domain for cf414
Datatype	xs:string (XMLSchema)
Unit of Measure	
Format	not specified
Maximum Character Quantity	not specified

Valid Values

Valid Values	value	meaning
	-1	Missing
	-2	Did not attend
	1	most of time
	2	sometimes
	3	rarely
	4	doesnt talk at all

Field Names

Field Names	field name	preferred
	cf414	true

Usage

Related data elements	Children in Focus part of dataset
	'Takes turns talking' Speech Q 25 mth precedes this data element in dataset
	'How often follows instructions' Speech Q 25 mth precedes this data element in dataset
	'Points to body parts' Speech Q 25 mth precedes this data element in a dataset
	'How describe childs talking' Speech Q 25 mth follows this data element in a dataset
	'Hoarse/husky voice' Speech Q 25 mth follows this data element in a dataset
	'Stuck/repeat words' Speech Q 25 mth follows this data element in a dataset

Classification

Classification	term
	25 months
	Children in Focus dictionary

Data Element by Classifier

Search within classification

(reset form)

Schemes

ALSPAC by age ▾

Classification

broader terms

Alspac by child age

selected term

134 months

related terms

8 wks gest

12 wks gest

18 wks gest

32 wks gest

4 weeks

8 weeks

4 months

6 months

8 months

12 months

15 months

18 months

21 months

24 months

25 months

30 months

31 months

33 months

37 months

38 months

42 months

Origin Names

ALSPAC A1a: Child's school is a place where they really like to go each day
ccj100

[add to cart](#)

A1a: Child's school is a place where they really like to go each day

ALSPAC A1a: Frequency respondent felt things spinning/moving around, lasting less than 2 minutes during past 12 months
r1000

[add to cart](#)

A1a: Frequency respondent felt things spinning/moving around, lasting less than 2 minutes during past 12 months

ALSPAC A1a: Frequency respondent has felt things spinning/moving for less than 2 mins in past 12 months
pp1000

[add to cart](#)

A1a: Frequency respondent has felt things spinning/moving for less than 2 mins in past 12 months

ALSPAC A1b: Child's school is a place where their teacher is fair to them
ccj101

[add to cart](#)

A1b: Child's school is a place where their teacher is fair to them

ALSPAC A1b: Frequency respondent felt things spinning/moving around, lasting up to 20 minutes during past 12 months
r1001

[add to cart](#)

A1b: Frequency respondent felt things spinning/moving around, lasting up to 20 minutes during past 12 months

Definitions Values

(undefined) *data type:* xs:string
units:
enumerations:
-1 No response-10 Not completed-11 Triplet / quadruplet1 Agree2 Mostly agree3 Mostly disagree4 Disagree99 DK

(undefined) *data type:* xs:string
units:
enumerations:
-1 No response-10 Not completed-11 Triplet / quadruplet0 Other text answer1 > than once a week2 > than once a month3 4-12 times4 1-3 times5 Not at all9 DK

(undefined) *data type:* xs:string
units:
enumerations:
-1 No response-10 Not completed-11 Triplet / quadruplet1 > Once a week2 > Once a month3 4-12 times4 1-3 times5 Not at all

(undefined) *data type:* xs:string
units:
enumerations:
-1 No response-10 Not completed-11 Triplet / quadruplet1 Agree2 Mostly agree3 Mostly disagree4 Disagree99 DK

(undefined) *data type:* xs:string
units:
enumerations:
-1 No response-10 Not completed-11 Triplet / quadruplet0 Other text answer1 > than once a week2 > than once a month3 4-12 times4 1-3 times5 Not at all9 DK


Model Listing

a b c d e f g h i j k l m n o p q r s t u v w x y z

Names	Definition
F File	DATA COLLECTED FROM THE QUESTIONNAIRE 'Looking After the Baby' at 8 months
Focus 10 +	The aim of 'Children in Focus' was to examine the children in a way that cannot be done using questionnaires to their parents. The sample provides both a validation for certain aspects of the self-completion questionnaires and an answer to some important questions. These are related, for example, to the ways in which childhood diet, growth, anaemia, otitis media with effusion, visual defects, parenting skills and early cognition are related to the development of intellectual competence, speech and language as well as motor development of the child
Focus 11 +	The aim of 'Children in Focus' was to examine the children in a way that cannot be done using questionnaires to their parents. The sample provides both a validation for certain aspects of the self-completion questionnaires and an answer to some important questions. These are related, for example, to the ways in which childhood diet, growth, anaemia, otitis media with effusion, visual defects, parenting skills and early cognition are related to the development of intellectual competence, speech and language as well as motor development of the child
Focus @ 7	The aim of 'Children in Focus' was to examine the children in a way that cannot be done using questionnaires to their parents. The sample provides both a validation for certain aspects of the self-completion questionnaires and an answer to some important questions. These are related, for example, to the ways in which childhood diet, growth, anaemia, otitis media with effusion, visual defects, parenting skills and early cognition are related to the development of intellectual competence, speech and language as well as motor development of the child
Focus @ 9	The aim of 'Children in Focus' was to examine the children in a way that cannot be done using questionnaires to their parents. The sample provides both a validation for certain aspects of the self-completion questionnaires and an answer to some important questions. These are related, for example, to the ways in which childhood diet, growth, anaemia, otitis media with effusion, visual defects, parenting skills and early cognition are related to the development of intellectual competence, speech and language as well as motor development of the child

Tag Cloud View


Whitehall Timeline








last hospital months 12 hrt year sm admission 1998 october patient name month symptoms 1950 study first age health reason day 4 doctor 1999 whether used much years names preparations life taken problem during 2nd stopped 1st child occasion time weeks period 10 prescribed recently old periods children cohort test work up hysterectomy everyday 3rd reasons preparation bothered many card chest breast 3 give mother urine pressure medicine being illness go days felt town pain blood s partner importance important menstrual admitted order 1-3 mammogram ranking started charge recent more 4th condition oophorectomy household ward private treated diagnosis case


Reference Documents

id	language	title
C5DD288C6	eng	ka094 Baby breas



SEMANTIC SOFTWARE GENERATION





[search](#)[browse](#)[discover](#)[understand](#)[login](#)

Data Element: CASP total score (CASP-19) (S7-d)

[as XSD](#)[as XML](#)

Administered Item - Preferred Name: CASP total score (CASP-19) (S7-d)

Administered Item Identifier	GB-OUCL-856DD873-1
Registration Status <i>explain</i>	Recorded
Definition	not-specified
Registered By	Dr. Steve Harris (Researcher, IDH) Oxford Comlab

Value Domain Attributes

Value domain record	Value Domain for CASP total score (CASP-19) (S7-d)
Conceptual Domain	Conceptual Domain for CASP total score (CASP-19) (S7-d)
Datatype	xs:double (XMLSchema)
Unit of Measure	
Format	not specified
Maximum Character Quantity	not specified
Representation Class	

Field Names

Field Names	field name	preferred
	MCASPTOT	true

Model Reference

Expresses data element concept (full record)	Data Element Concept for CASP total score (CASP-19) (S7-d)
Object class	default object class
Property	default property
Precision	0
Example	not specified
Typed by Representation Class	not-specified

[search](#)[browse](#)[discover](#)[understand](#)[login](#)

Data Element: CASP total score (CASP-19) (S7-d)

[as XSD](#)[as XML](#)

Administered Item - Preferred Name: CASP total score (CASP-19) (S7-d)

Administered Item Identifier	GB-OUCL-856DD873-1
Registration Status <i>explain</i>	Recorded
Definition	not-specified
Registered By	Dr. Steve Harris (Researcher, IDH) Oxford Comlab

Value Domain Attributes

Value domain record	Value Domain for CASP total score (CASP-19) (S7-d)
Conceptual Domain	Conceptual Domain for CASP total score (CASP-19) (S7-d)
Datatype	xs:double (XMLSchema)
Unit of Measure	
Format	not specified
Maximum Character Quantity	not specified
Representation Class	

Field Names

Field Names	field name	preferred
	MCASPTOT	true


Model Reference

Expresses data element concept (full record)	Data Element Concept for CASP total score (CASP-19) (S7-d)
Object class	default object class
Property	default property
Precision	0
Example	not specified
Typed by Representation Class	not-specified


```

- <xs:schema>
+ <xs:annotation></xs:annotation>
  <xs:element name="name_of_your_element" ref="MCASPTOT"/>
- <xs:element name="MCASPTOT" type="GB-OUCL-4EA1E0CD-1" sawsdl:modelReference="GB-OUCL-856DD873-1">
  + <xs:annotation></xs:annotation>
  </xs:element>
- <xs:simpleType name="GB-OUCL-4EA1E0CD-1" sawsdl:modelReference="GB-OUCL-4EA1E0CD-1">
  <xs:extension base="xs:double"/>
- <xs:annotation>
  - <xs:documentation>
    - <cgMDR:Value_Domain item_registration_authority_identifier="GB-OUCL" data_identifier="4EA1E0CD" version="1">
      - <cgMDR:administered_item_administration_record>
        <cgMDR:registration_status>Recorded</cgMDR:registration_status>
        <cgMDR:administrative_status>noPendingChanges</cgMDR:administrative_status>
        <cgMDR:creation_date>2010-09-22</cgMDR:creation_date>
        <cgMDR:effective_date>2010-09-22</cgMDR:effective_date>
        <cgMDR:last_change_date>2010-09-22</cgMDR:last_change_date>
        <cgMDR:explanatory_comment>Created by the SAS Importer</cgMDR:explanatory_comment>
        <cgMDR:unresolved_issue/>
        <cgMDR:origin>GB-OUCL-230001-1</cgMDR:origin>
      </cgMDR:administered_item_administration_record>
      <cgMDR:administered_by>GB-OUCL-200002-1</cgMDR:administered_by>
      <cgMDR:registered_by>GB-OUCL-100009-1</cgMDR:registered_by>
      <cgMDR:submitted_by>GB-OUCL-230002-1</cgMDR:submitted_by>
      <cgMDR:described_by/>
    - <cgMDR:having>
      <cgMDR:context_identifier>GB-OUCL-CC93897D9-1</cgMDR:context_identifier>
    - <cgMDR:containing>
      - <cgMDR:language_section_language_identifier>
        <cgMDR:country_identifier>GB</cgMDR:country_identifier>
        <cgMDR:language_identifier>eng</cgMDR:language_identifier>
      </cgMDR:language_section_language_identifier>
    </cgMDR:containing>
  </xs:documentation>
</xs:annotation>
</xs:simpleType>
</xs:element>
</xs:schema>

```



```
<xforms:input
  ref="//cgMDR:change_description">
  <xforms:label>Change Description</xforms:label>
</xforms:input>
```

```
<xsl:template match=
"xforms:input[ends-with(./@ref,'cgMDR:change_description')] ">
  <xforms:textarea
    ref="//cgMDR:change_description">
    <xforms:label>Change Description </xforms:label>
  </xforms:textarea>
</xsl:template>
```

```
<xforms:textarea
  ref="//cgMDR:change_description">
  <xforms:label>Change Description</xforms:label>
</xforms:textarea>
```

sawSDL + cgMDR

```
<?xml version="1.0" encoding="UTF-8"?>
<cg:trialProtocol xmlns:cg="http://www.cancergrid.org/protocol"


    xmlns:sawSDL="http://www.w3.org/ns/sawSDL"
...
<cg:name>Zubrod performance status score</cg:name>
<cg:cdeDataType>
  <xs:simpleType name="enumZubrodStatus"

    sawSDL:modelReference
      ="2.16.840.1.113883.3.26.2:2003315:42">

    <xs:restriction base="xs:string">
      <xs:enumeration value="0"/>
      <xs:enumeration value="1"/>
      <xs:enumeration value="2"/>
      <xs:enumeration value="3"/>
      <xs:enumeration value="4"/>
    </xs:restriction>
  </xs:simpleType>
</cg:cdeDataType>
...
```


tooling for the semantic framework

SEMANTICS IN MODELS



Click Use

plays / is played by



is scoped by / scope



CancerGrid Query Service

Free Text Classification

Controls

EVS-DescLogicConcept

person

Query completed. Search

Results

- CTCAE Grade 1 Personality and Behavioral Change
- CTCAE Grade 2 Personality and Behavioral Change
- CTCAE Grade 3 Personality and Behavioral Change
- CTCAE Grade 4 Personality and Behavioral Change
- CTCAE Grade 5 Personality and Behavioral Change
- Chairperson
- Contact Person
- Person Contact Information
- Person Name
- Other Personal Medical History
- Passive-Aggressive Personality
- Person**
- Person Info
- Person Observer
- Person Observer Organization Name
- Person Observer Role in Organization

<< >> Use

Details

Definition

A single human being.

BiologicEntity

Person

- + academicDegree: DSET<CD>
- + deathIndicator: BL
- + educationLevelCode: CD
- + ethnicGroupCode: DSET<CD>
- + identifier: II
- + initials: ST
- + maritalStatusCode: CD
- + name: EN.PN
- + occupationDateRange: IVL<TS>
- + postalAddress: AD
- + primaryOccupationCode: CD
- + raceCode: DSET<CD>
- + telecomAddress: DSET<TEL>

Organization

- abbreviatedName: EN.ON
- description: ST
- identifier: DSET<II>
- name: EN.ON
- postalAddress: AD
- statusCode: CD
- statusDateRange: IVL<TS>
- telecomAddress: DSET<TEL>
- typeCode: CD

plays / is pl

is soo

Class : Person

General Detail Require Constraints Link Scenario Files

Name: Person

Stereotype: Abstract

Author: Status: Proposed

Scope: Public Complexity: Easy

Alias: Language: Java

Persistence: Keywords:

Phase: 1.0 Version: 1.0 **Advanced**

Notes:
A human being. (ConceptRefs: [C25190])

Apply OK Cancel Help

CancerGrid Query Service

Free Text Classification

Controls
EVS-DescLogicConcept
person
Query completed. Search

Results
CTCAE Grade 1 Personality and Behavioral Change
CTCAE Grade 2 Personality and Behavioral Change
CTCAE Grade 3 Personality and Behavioral Change
CTCAE Grade 4 Personality and Behavioral Change
CTCAE Grade 5 Personality and Behavioral Change
Chairperson
Contact Person
Person Contact Information
Person Name
Organic Personality Syndrome
Other Personal Medical History
Passive-Aggressive Personality
Person
Person Info
Person Observer
Person Observer Organization Name
Person Observer Role in Organization

Details
Definition Props/Values
A single human being.

Diagram: "PO-relevant" created: 7/21/2008 10:19:16 AM

BiologicEntity

Person

- + academicDegree: DSET<CD>
- + deathIndicator: BL
- + educationLevelCode: CD
- + ethnicGroupCode: DSET<CD>
- + identifier: II
- + initials: ST
- + maritalStatusCode: CD
- + name: EN.PN
- + occupationDateRange: IVL<TS>
- + postalAddress: AD
- + primaryOccupationCode: CD
- + raceCode: DSET<CD>
- + telecomAddress: DSET<TEL>

Organization

- + abbreviatedName: EN.ON
- + description: ST
- + identifier: DSET<II>
- + name: EN.ON
- + postalAddress: AD
- + statusCode: CD
- + statusDateRange: IVL<TS>
- + telecomAddress: DSET<TEL>
- + typeCode: CD

plays / is pl...

is soo...

CancerGrid Query Service

Free Text Classification

Controls

caDSR

academic degree

Query completed.

Search

Results

DENT_ACADDGR_TXT
P_ACD_DEG_SF_ABR_TXT
 T_DC_ACAD_DEG_SUF_CD
 HCP_AC_DG_SF_ABR_TXT


<< >> Use

Details


Definition Props/Values

Code	Meaning
MD	Doctor of Medicine
DO	Doctor of Osteopathic Medicine
DMD	Doctor of Dental Medicine
DED	Doctor of Education
DD	Doctor of Divinity
DC	Doctor of Chiropractic

behind the scenes



query service manager



Book1 - Microsoft Excel

File Home Insert Page Layout Formulas Data Review View Developer Oxford Metadata Load Test Team Design

Query Metadata Create CDE Settings Export XML Submit Model Metadata Services

C3 fx

	A	B	C	D	E	F	G
1	Age	Gender	Blood Specimen Type				
2							
3							
4			PSA (total free)				
5			PSA (total)				
6			PSA (free)				
7			Testosterone				
8			Dihydrotestosterone				
9			Estrone				
10			Estradiol				
11							
12							
13							
14							
15							
16							
17							
18							
19							
20							

Query Metadata

Free Text Classification

Controls

caDSR-DataElement

Blood*Type*

Query completed Search

Results

- Blood Transfusion Timepoint Administered Type
- Blood Test Type
- Blood Test Response Text Type
- Blood Specimen Type
- Blood Specimen Submission Materials Required Ty
- Blood Specimen Collection Type
- Blood Specimen Collection Period Type
- Blood Pressure Instrument Type
- Blood in Stool Response Text Type
- Blood Collection Tube Type
- Blood Specimen Type

< > Use

Details

Definition Props/Values

Model Submission Form

Preferred Name: Test Model

Definition: This is a test model

Context: Default registry context

Annotation Name	Annotated Address
Age	Sheet1!\$A\$1:\$A\$21
Blood_Specimen_Type	Sheet1!\$C\$1:\$C\$21
Gender	Sheet1!\$B\$1:\$B\$21

I am: Steve Harris (Researcher, IDH)

Who is working for: Steve Harris (Researcher, IDH)

Submit Excel model on behalf of: Dr. Steve Harris (Oxford Comlab)

User name: admin

Password: ●●●●●●

Submit Cancel

CancerGrid trial designer

Trial event:

Intervention codes:

Insert intervention code

Form control name:

Namespace prefix:

Namespace:

Add and select controls in this table then edit the details for the control below.

Eligibility	Eligibility
InclusionCriteria	Inclusion Criteria
ExclusionCriteria	Exclusion Criteria
ParentConsent	the parent or guardian of the child to be enrolled into the study is willing and able...
ChildAgeRequirement	child aged 3 years 4 months and above
GPConsultantNotification	willing to allow his or her GP and Consultant to be notified of participation in the ...
HepatitisVaccinationCommenced	commenced Hepatitis B post exposure prophylaxis at birth
StudyRequirements	Able (in the Investigator's opinion) and willing to comply with all study requireme...

Insert control

General control details

Control name:

Title:

Tool tip:

[Click here to insert expression describing when to disable the control](#)

[Click here to insert expression describing when control data is invalid](#)

Field details

Min Occurs: Max Occurs:

The type of the field is determined by a data element:

Data element	
ID	Preferred name
GB-CANCERGRID-OX-57BC835E5-1	Able and willing to comply with study requirements
Alternative names:	
Definition:	
Able (in the Investigator's opinion) and willing to comply with all study requirements	
Code	Meaning
no	no
yes	yes

Query Service Control

Free Text Classification

Controls

Query completed.

Results

Able and willing to comply with stu
Breast Tumor Location data elem
Breast Tumour Location
Chemotherapy will be given to the
Common Toxicity Criteria Adverse I
Disease Stage data element
ETHNIC CATEGORY
Patient Sex data element
Patient Trial Number (CRUK Trials
Patient date of second surgery


Details

Definition Props/Values

Able (in the Investigator's opinion) and willing to comply with all study requirements

GENERATION FROM EXPERIMENTAL MODELS

meta-models of experiments



user interface generation

The diagram illustrates the process of user interface generation from an internal model. It starts with an XSD schema for a trial protocol, which is then processed into an XML document. This XML document is used by Microsoft Office InfoPath 2003 to generate a user interface form titled 'Protocol Designer'.

The 'Protocol Designer' form is divided into two main sections: 'General' and 'Main Contact'.

General

ISRCTN	51,146,252
MREC	
EUDRACT	
Name Short	tAnGo
Name Long	A randomised phase III trial of gemcitabine in paclitaxel-containing
Target Recruitment	3,000
Funder(s)	Cancer Research UK
Sponsor(s)	Cancer Research UK

Main Contact

Family Name	Sarah
Given Name	Bathers
Other Names	
Address	Cancer Research UK Clinical Trials Unit Institute for Cancer Stud
Post Code	B15 2TT
Telephone	0121 414 7673
Fax	0121 414 3700
Email	S.Bathers@bbham.ac.uk

Form template's location: <http://163.1.125.57>

View All Site Content

Documents

- Shared Documents
- Centres
- Researchers
- Case Report Forms
- SAE
- Screening Failures

Lists

- Calendar
- Tasks
- KPI List

Discussions

- Team Discussion

Sites

People and Groups

- Recycle Bin

Oxford Vaccine Group > ACWY



Understanding the Immune Response to Meningitis Vaccines

Files and records for the ACWY study

Shared Documents

Type	Name	Modified	Modified By
	4-4-mpc-acwy-vax-vaccine	25/08/2009 11:13	CG1'pharris
	Adult ACWY CRF 19 06 08 clean	02/07/2009 17:12	CG1'pharris
	Adult MenACWY 19 June 2008	02/07/2009 17:14	CG1'pharris
	MenACWY IB Edition 12 23 FEB 09	14/07/2009 09:37	CG1'pharris
	Participant Contact Sheet	02/07/2009 17:14	CG1'pharris

Add new document

Key Performance Indicators

Indicator	Status
Total Recruitment	
Protocol Violations	
Serious Adverse Events	
Recruitment Rate	

Case Report Forms

New Upload Actions Settings											
Name	Participant No	DOB	Initials	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5	Withdrawn	Violations	AE Count
Count = 6				Count = 6	Count = 4	Count = 0	Count = 0	Count = 0	Count = 0	Sum =	Sum = 1
001	001			20/08/2009	27/08/2009						1
002	002			20/08/2009	27/08/2009						
003	003			25/08/2009	01/09/2009						
004	004			27/08/2009	02/09/2009						
005	005			01/09/2009							
006	006			01/09/2009							

SAE

New Upload Actions Settings									
Name	Centre	Researcher	Participant No	DOB	Initials	Onset	Resolved	FU Planned	FU Completed
To create a new item, click "New" or "Upload" above. There are no items to show in this view of the "SAE" document library.									

Oxford Vaccine Group

Hepatitis B Booster Study

Home **Hepatitis B Booster Study**

- View All Site Content
- Surveys**
- Documents**
 - Shared Documents
 - Serious Adverse Event
 - Centre Details
 - Researcher Details
 - Withdrawal
 - Participant Case Report
- Lists**
 - Calendar
 - Tasks
- Discussions**
 - Team Discussion
- Sites**
- People and Groups**
- Recycle Bin**

Oxford Vaccine Group > Hepatitis B Booster Study



Shared Documents

Type	Name	Modified By
	Source Document	CG1\vgtest
	Parent Contact Sheet	CG1\vgtest
	Hepatitis B protocol -24th Oct 2008	CG1\sharris

Participant Status

Centre Number	Researcher Number	Participant Number	Visit 1 Date	Visit 2 Date	Planned V 2 Date	Participant Initials
00001	004	001	3/16/2009 12:00 AM			AB

Identification Visit 1 Visit 2 Notes

Centre Number: 00001 Researcher Number: 004 Participant Number: 001



Hepatitis B Booster Study

Visit 1 Date: 16/03/2009
Informed Consent: yes

Inclusion Criteria

- 1. Parent Consent: yes
- 2. Child Age Requirement: yes
- 3. GP/Consultant Notification: yes
- 4. Hepatitis Vaccination Commenced: yes
- 5. Study Requirements: yes

Alerts & Messages

Welcome to OpenClinica, Root User. You last logged in on 31-May-2011.

Instructions

If needed you may change the study/site or request access to a new study with a different role.

Info

Study: ICGC Test Study

Start Date: N/A

End Date: N/A

PI: Charles Crichton

Protocol Verification/IRB Approval Date:

Icon Key

Statuses

Welcome to ICGC Test Study

You are logged in as a Data Manager

0 Notes & Discrepancies Assigned to Me.

Site	Enrolled	Expected Enrollment	Percentage
ICGC_FormTestSite	5	6	83%

Study	Enrolled	Expected Enrollment	Percentage
ICGC Test Study	5	0	0%

Event Status	# of Events	Percentage
scheduled	2	20%
data entry started	8	80%
completed	0	0%
signed	0	0%
locked	0	0%
skipped	0	0%
stopped	0	0%

Study Subject Status	# of Study Subjects	Percentage
available	5	100%
signed	0	0%
removed	0	0%

File Home Insert Page Layout Formulas Data Review View CancerGrid Load Test

Clipboard Font Alignment Number Styles Cells Editing

Conditional Formatting as Table Cell Styles Insert Delete Format

AutoSum Fill Clear Sort & Filter Find & Select

B3 Location of hospital from which patient and/or sample ascertained

	B	C	D	E	F	G	H	I	J	K	
				RIG HT_I TEM _TE			HEA DE				
1	DESCRIPTION_LABEL	LEFT_ITEM_TEXT	UNITS	XT	SECTION_LABEL	GRO R	SUBHEADER		PARENT_ITEM	COLUMN_NUMBER	
2	Please state whether this data is being entered prospectively (at time of diagnosis) or whether the data has been entered retrospectively (from case notes, patient sample in archive)	<i>Prospective or retrospective</i>			Demographics and Identifiers		Data entry			1	
3	Location of hospital from which patient and/or sample ascertained	Location of hospital from which patient and/or sample ascertained			Demographics and Identifiers		Location			1	
4	Patient surname	<div style="border: 1px solid black; padding: 5px;"> <p>Enter Description Label Enter a description or definition for this item. The description should give an explanation of the data element and the value(s) it captures. It is not shown on the CRF but is in the data dictionary. It should be 1 to 4000 characters long. It is required.</p> </div>			Demographics and Identifiers		Patient details			1	
5	Patient forename		Demographics and Identifiers							2	
6	Patient NHS Number		Demographics and Identifiers							1	
7	Patient postcode		Demographics and Identifiers							2	
8	Patient gender		Demographics and Identifiers							1	
9	Date of birth		Date of birth			Demographics and Identifiers					2
10	Ethnicity of patient		Ethnicity			Demographics and Identifiers		Ethnicity			1
11	Comment on ethnicity of patient		Comment on ethnicity when 'Other' selected			Demographics and Identifiers				A_1a_DI_PatientEthnicity	1
12	Date of diagnosis of oesophago-gastric cancer	Date of diagnosis of oesophago-gastric cancer			Demographics and Identifiers		Diagnosis			1	
13	Was informed consent obtained for OCCAMS (which incorporates ICGC)	Was informed consent obtained for OCCAMS (which incorporates ICGC)			Demographics and Identifiers		Informed consent			1	
14											
15											
16											
17											
18											

Initial Data Entry for A_1a_DI_Demographics_Identifiers DRAFT_2 ?

CRF Info

A_1a_DI_Demographics_Identifiers DRAFT_2

 Discrepancy Notes: **0 New, 0 Updated, 0 Resolution Proposed, 0 Closed, 0 Not Applicable**

Study Subject ID: test03

Study/Site: ICGC Test Study

Age At Enrollment: N/A

Event: Recruitment(23-May-2011)

Date of Birth: Sex: F

Interviewer Name: *

Interview Date: *



Demogra...(0/12)

-- Select to Jump --

Title: Demographics and Identifiers

Page:



Mark CRF Complete

Save

Exit



Data entry

DI.1: Prospective or retrospective

Please select



Location

DI.2: Location of hospital from which patient and/or sample ascertained

Please select



Patient details

DI.3: Surname



DI.4: Forename



DI.5: NHS Number



DI.6: Postcode




- Alerts & Messages
- Instructions
- Info
 - Study Events:
 - Recruitment
 - A_1b_EX_Exposures
 - A_1c_RD_Initial_Referral_Diagnosis
 - A_1a_DI_Demographics_Identifiers
 - Staging and management planning
 - A_2a_PS_Pretreatment_Staging_Investigations
 - A_2b_TP_Treatment_Plan
 - Treatment
 - A_3b_CR_Oncological_Treatments_Definitive_Chemoradiotherapy
 - A_3e_PA_Palliative
 - A_3c_ST_Surgical_Treatment
 - A_3a_NT_Oncological_Treatments_Neoadjuvant_Therapy
 - A_3d_AD_Oncological_Treatments_Adjuvant
 - Resection pathology
 - A_4a_RP_Surgical_Treatment
 - Research sample collection
 - A_5b_SS_ResearchSampleInformation
 - A_5c_SB_ResearchSampleInformation
 - A_5a_SE_Research_Sample_Information_Endoscopy
 - Disease outcome

Create Dataset: Select Items ?

Please select one CRF from the **left side info panel**, then select one or more items in a CRF that you would like by going to the "View Selected Items" (hyperlink) page and clicking "Select All".

You may also click Event Attributes/Subject Attributes to specify which event/subject attribute will be shown in

← Use task pane on the left side to select CRFs



C:\Users\crc\Downloads\Example_outputD20110613111556+0100.xml - Windows Internet Explorer

C:\Users\crc\Downloads\Example_outputD20110613111556+0100.xml

OpenClinica

```
<?xml version="1.0" encoding="UTF-8" ?>
- <ODM FileOID="Example_outputD20110613111556+0100" Description="Data" CreationDateTime="2011-06-13T11:15:56+01:00" FileType="Snapshot"
  ODMVersion="1.3" xmlns="http://www.cdisc.org/ns/odm/v1.3" xmlns:OpenClinica="http://www.openclinica.org/ns/openclinica_odm/v1.3"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.cdisc.org/ns/odm/v1.3 OpenClinica-ODM1-3-0-OC1.xsd">
- <Study OID="S_ICGCTEST">
- <GlobalVariables>
  <StudyName>ICGC Test Study</StudyName>
  <StudyDescription>This is for testing the forms.</StudyDescription>
  <ProtocolName>ICGC Test Study</ProtocolName>
</GlobalVariables>
- <BasicDefinitions>
- <MeasurementUnit OID="MU_CIGARETTES" Name="cigarettes">
- <Symbol>
  <TranslatedText>cigarettes</TranslatedText>
</Symbol>
</MeasurementUnit>
- <MeasurementUnit OID="MU_CM" Name="cm">
- <Symbol>
  <TranslatedText>cm</TranslatedText>
</Symbol>
</MeasurementUnit>
- <MeasurementUnit OID="MU_DAY(S)" Name="day(s)">
- <Symbol>
  <TranslatedText>day(s)</TranslatedText>
</Symbol>
</MeasurementUnit>
- <MeasurementUnit OID="MU_HOURS" Name="hours">
- <Symbol>
  <TranslatedText>hours</TranslatedText>
</Symbol>
</MeasurementUnit>
- <MeasurementUnit OID="MU_KG" Name="kg">
- <Symbol>
  <TranslatedText>kg</TranslatedText>
</Symbol>
```

Done

Internet | Protected Mode: On

105%

semantic frameworks

- *not enough metadata* – support the use of standards and the reuse of past experimental definitions as part of the design of systems
- *not enough data standards* – need to be available at the point of use and for use to be easier than going it alone
- *not enough data management* – generate, configure and integrate common off the shelf software, offer server resources via virtual machines and web services

PTCRi



Particle Therapy Cancer Research Institute

Webpage: <http://www.ptcri.ox.ac.uk/>

PARTNER



Particle Training Network for European Radiotherapy

Particle Therapy Marie Curie Early Initial Training Network Fellowship of the European Community's Seventh Framework Programme under contract number (PITN-GA-2008-215840-PARTNER).

Webpage: <http://www.ptcri.ox.ac.uk/>

ULICE



Union of Light Ion Centres in Europe (ULICE)

Co-funded by the E. C. within the Framework Programme 7 Capacities Specific Programme. (*Grant Agreement 228436*).

Webpage: <http://ulice.web.cern.ch>